Anergis SA of Switzerland has raised CHF 8 million (€6.5 million) from its venture capital backers in order to advance its lead vaccine product, AllerT, for birch pollen allergy into Phase 3 development. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
